| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-07-03 | AstraZeneca (UK) Recordati (Italy) | Seloken®/Seloken® ZOK (metoprolol succinate) and associated Logimax® fixed dose combination (metoprolol succinate and felodipine) treatments | hypertension, angina, heart failure | product acquisition | Cardiovascular diseases | Product acquisition |
| 2017-07-02 | Exscientia (UK) GSK (UK) | novel and selective small molecules for up to 10 disease-related targets using an artificial intelligence platform | collaboration | Collaboration agreement | ||
| 2017-06-30 | Molmed (Italy) TTY Biopharm | Zalmoxis® - TK cell therapy | hematological cancers | licensing - commercialisation - distribution | Cancer - Oncology | Licensing agreement |
| 2017-06-30 | Ipsen (France) Saol Therapeutics (USA - GA) | Dysport® (abobotulinumtoxin A ) | adult spasticity, pediatric lower limb spasticity | co-promotion | Neurological diseases - Neuromuscular diseases | Co-promotion agreement |
| 2017-06-30 | Quantum Genomics (France) | nomination | Cardiovascular diseases | Nomination | ||
| 2017-06-29 | Abbvie (USA - IL) CytomX (USA - CA) | Probody™ Drug Conjugates against CD71 including CX-2029 | development - commercialisation | Cancer - Oncology | Milestone | |
| 2017-06-29 | ITeos Therapeutics (Belgium) | nomination | Cancer - Oncology | Nomination | ||
| 2017-06-29 | TiGenix (Belgium) | establishment of a new subsidiary in the US | Establishment of a new subsidiary in the US | |||
| 2017-06-29 | Servier (France) Transgene (France) | allogenic CAR-T cell therapies | research - R&D | Research agreement | ||
| 2017-06-29 | Horama (France) | Chief Medical Officer, Head of CMC Regulatory Affairs, Chief Financial Officer | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2017-06-28 | Cellectis (France) | member of the board of directors | nomination | Cancer - Oncology - Immunological diseases | Nomination | |
| 2017-06-28 | Inovio Pharmaceuticals (USA - PA) | nomination | Cancer - Oncology - Infectious diseases | Nomination | ||
| 2017-06-28 | Sarepta Therapeutics (USA - MA) | president and chief executive officer | nomination | Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | |
| 2017-06-27 | Ablynx (Belgium) Merck&Co (USA - NJ) | Nanobody candidates (including bi- and tri-specifics) directed toward immune checkpoint modulators | research - R&D - licensing | Cancer - Oncology | Milestone | |
| 2017-06-27 | Sarepta Therapeutics (USA - MA) | opening of new premises | Rare diseases - Genetic diseases - Neuromuscular diseases | Opening of new premises | ||
| 2017-06-27 | Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) | Cancer - Oncology | Restructuring | |||
| 2017-06-26 | University of Cambridge (UK) Genomics England Ltd (UK) Illumina (USA) | 100,000 Genomes Project | rare genetic diseases, cancers | collaboration | Genetic diseases - Rare diseases - Cancer - Oncology | Collaboration agreement |
| 2017-06-26 | Epizyme (USA - MA) Genentech, a member of Roche Group (USA - CA - Switzerland) | tazemetostat - EPZ-6438 (E7438) and Tecentriq™ (atezolizumab) | relapsed or refractory diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma, relapsed/refractory metastatic non-small cell lung cancer (NSCLC) | clinical research - collaboration | Cancer - Oncology | Clinical research agreement |
| 2017-06-26 | Takeda Pharmaceutical (Japan) Biological E. (India) | measles vaccines and acellular pertussis vaccine | measles, pertussis | licensing | Infectious diseases | Licensing agreement |
| 2017-06-26 | Curevac (Germany) | GMP III and GMP IV facilities | construction of new premises | Construction of new premises |
